Mesar (Olmesartan Medoxomil)

Olmesartan medoxomil is an angiotensin II receptor blocker used to manage high blood pressure conditions.

• Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension, helping to lower cardiovascular risk.
• Hypertensive heart disease: assists in controlling blood pressure to prevent progression of cardiac complications.
• Stroke prevention: contributes to reducing the risk of stroke associated with uncontrolled hypertension.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells. By preventing angiotensin II binding, it inhibits vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Olmesartan medoxomil may cause a range of adverse reactions.

Common Side Effects

• Dizziness: light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: feeling unusually tired.
• Diarrhoea: loose stools.
• Upper respiratory tract infection: nasopharyngitis.
• Hyperkalaemia: elevated blood potassium levels.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or throat.
• Severe hypotension: markedly low blood pressure.
• Acute renal failure: sudden loss of kidney function.
• Hepatic injury: abnormal liver enzymes or hepatitis.
• Neutropenia: low neutrophil count increasing infection risk.
• Myocardial infarction: rare reports of heart attack.

Before initiating therapy with Olmesartan medoxomil, certain precautions should be observed.

• Renal function monitoring: assess serum creatinine and eGFR periodically.
• Electrolyte assessment: check potassium levels to avoid hyperkalaemia.
• Concomitant diuretics: adjust dose if using potassium‑sparing diuretics.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Pregnancy: avoid use during pregnancy due to potential fetal toxicity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use may increase risk of renal impairment and hyperkalaemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• ACE inhibitors: concurrent use raises the risk of angioedema.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: can increase lithium levels, risking toxicity.
• Cyclosporine: may elevate serum creatinine.
• Diuretics: may enhance hypotensive effect, requiring dose adjustment.